Quetiapine treatment of children and adolescents with Tourette's disorder

• Published in: Journal of child and adolescent psychopharmacology Vol. 13; no. 3; pp. 295 - 299
• Main Authors: Mukaddes, Nahit Motavali, Abali, Osman
• Format: Journal Article
• Language: English
• Published: United States Mary Ann Liebert, Inc 01.09.2003
• Subjects: Adolescent; Antipsychotic Agents - adverse effects; Antipsychotic Agents - therapeutic use; Child; Dibenzothiazepines - adverse effects; Dibenzothiazepines - therapeutic use; Dose-Response Relationship, Drug; Female; Humans; Male; Neuropsychological Tests; Psychiatric Status Rating Scales; Quetiapine Fumarate; Tourette Syndrome - drug therapy; Tourette Syndrome - psychology
• ISSN: 1044-5463; 1557-8992
• DOI: 10.1089/104454603322572624

The purpose of this study was to investigate the short-term safety and effectiveness of quetiapine in the treatment of children and adolescents with Tourette's disorder. This was an 8-week, open-label trial that included 12 subjects with a mean age of 11.4 +/- 2.4 years. The subjects were seen every week throughout the study. Clinical responses, as measured by the Turkish version of the Yale Global Tic Severity Scale, revealed a statistically significant reduction in tic scores ranging from 30-100%. Mean dose of quetiapine at the end of the study was 72.9 +/- 22.5 mg/day. Three subjects complained of sedation in the first week of treatment. The favorable results of this open-label study should be interpreted with caution due to the uncontrolled nature of the study. Spontaneous waxing and waning of symptoms should also be considered. Further controlled studies are required.